Ivone Silva *, Tiago Loureiro **, Isabel Almeida ***, Armando Mansilha ****, Rui Almeida *****, Carlos Vasconcelos ******
*Assistente Hospitalar Graduado do Serviço de Angiologia e Cirurgia Vascular do Hospital Santo António – Centro Hospitalar do Porto; Co-responsável pela Consulta de Grupo de Raynaud; Consulta da Unidade de Imunolgia Clínica
** Interno Complementar do Serviço de Angiologia e Cirurgia Vascular do Hospital Santo António – Centro Hospitalar do Porto
*** Assistente Hospitalar Graduado do Serviço de Medicina do Hospital Santo António – Centro Hospitalar do Porto; Co-responsável pela Consulta de Grupo de Raynaud; Membro da Unidade de Imunologia Clínica
**** MD, PHD, FEBS, Assistente Hospitalar de Angiologia e Cirurgia Vascular, Professor Auxiliar Convidado da Faculdade de Medicina da Universidade do Porto; Secretário Geral da SPACV
***** Chefe de Serviço, Director do Serviço de Angiologia e Cirurgia Vascular do Hospital Santo António – Centro Hospitalar do Porto, Presidente da SPACV
****** MD, PHD, Chefe de Serviço, Responsável da Unidade de Imunologia Clínica – Hospital Santo António– Centro Hospitalar do Porto; Professor Associado Convidado de Clínica Médica do Instituto Biomédicas Abel Salazar
]]> |RESUMO|
O Fenómeno de Raynaud (FR) é uma manifestação clínica comum, traduzida por vasoespasmos recorrentes dos dedos, na maioria das vezes provocados pela exposição ao frio ou estímulos emocionais.
Pode ser primário (idiopática) ou secundária a diversas doenças ou condições, incluindo doenças do tecido conjuntivo, como esclerose sistémica.
A patogênese da FR é mal compreendido. Actualmente pensa-se que a lesão endotelial e a disfunção vascular associada podem ser as primeiras alteração patogénicas e responsável pelas complicações vasculares nos doentes com RP.
As alterações funcionais (vasoconstrição) e as mudanças estruturais (proliferação intimal e obstrução dos capilares e artérias), traduzem-se clinicamente como RP e úlceras digitais.
O FR é em muitos casos a primeira manifestação da doença secundária associado e precede as outras manifestações clínicas em anos.
Palavras-chave: Fenómeno de Raynaud
Raynaud's Phenomenon
|ABSTRACT|
]]> Raynaud´s Phenomenon (RP) is a common clinical disorder, manifested by recurrent vasospasm of fingers and toes, often triggered by exposure to cold temperatures or emotional stress. It can be primary (idiopathic) or secondary to several diseases or conditions, including connective tissue diseases such as systemic sclerosis. The pathogenesis of RP is poorly understood.It is generally accepted that endothelial damage and vascular dysfunction may be the earliest pathogenetic alteration and ethological factor responsible for vascular complications in RP patients.
Functional abnormalities (vasoconstriction) and structural changes (intimal proliferation, obstruction) are expressed clinically as RP and digital ulcers. RP is the first manifestation of the secondary associated disease and precedes other clinical manifestations by years.
Key words: Raynaud's Phenomenon
Texto completo disponível apenas em PDF.
Full text only available in PDF format.
BIBLIOGRAFIA
[1] A Herrick BMJ Clinical Evidence Raynaud Phenomenon (Secondary) 2007.
]]>[2] Pope, J: The diagnosis and Treatment of Raynaud´s Phenomenon. Drugs 2007: 517-525. [ Links ]
[3] Klippel, J.H. (2003) Raynaud’s phenomenon. In: Freedberg, I.M., Eisen, A.Z., Wolff, K. et al (Eds.) Fitzpatrick’s dermatology in general medicine. 6th edn. London: McGraw-Hill. 1764-1769.
[4] Generini S, Rosso A , Pignone A, Matucci MC. Current Treatment options in Raynaud´s phenomenon. Current treatment options in cardiovascular medicine 2003; 5: 147-161.
[5] Matucci-Cerinic M, Seibold – JR: Digital ulcers and outcomes assessment in scleroderma. Rheumatology 2008: 47; v46-v47.
[6] A. Mansilha, S. Sampaio; Vasospastic disorders of the upper extremities In C.Liapis, K. Balzer, F. Benedetti-Valentini, J. Fernandes e Fernandes (eds): “European Manual of Vascular Surgery”; pp. 237-46. Springer-Verlag, 2005
[7] Maricq HR, Harper FE, Khan MM, Tan EM, LeRoy EC. Microvascular abnormalities as possible predictors of disease subset in Raynaud phenomen and early connective tissue disease. Clin Exp Rheumat: 1983: 1; 195- 205.
[8] Bulpitt KJ, Philip JC, Lachenbruch PA, Paulus HA, Peter JB, Agopian MS, Singer JZ, Steen VD, Clegg DO, Ziminski CM, Alarcon GS, Luggen ME, Polisson RP Willkens RF, Reading JC, Williams HJ, Ward JR. Early Undifferentiated Connective Tissue Disease: III. Outccome and prognostic indicators in Early Scleroderma (Systemic Sclerosis). The Journal of Rheumatology.
[9] A, Bell A, Bruce I, McGrann S, Allen J: Digital vascular responses and serum Endothelin-1 concentrations in primary and secondary Raynaud´s phenomenon. Ann Rheum Dis 2000; 59: 870-874.
[10] V. Smith, V., Pizzorni, Carmen, De Keyser, Filip, Decuman, Saskia, Van Praet, Jens T., Deschepper, Ellen, et al; Validation of the Qualitative and Semiquantitative Assessment of the Scleroderma Spectrum Patterns by Nailfold Videocapillaroscopy: Preliminary Results [abstract]. Arthritis Rheum 2009;60 Suppl 10 :445.
[11] Ingegnoli F, Boracchi P, Gualtierotti R, Lubatti c, Meani L, Zahalkova L et al: Prognostic model based on nailfold capillaroscopy for identifying Raynaud´s phenomenon patients at high risk for the development of a scleroderma spectrum disorder: PRINCE (Prognostic Index for Nailfold Capillaroscopy Examination) Arthritis Rheum 2008: 58; 2174-2182.
]]> [12] Sulli A, Secchi M E, Pizzorni C, Cutolo M: Scoring the nailfold microvascular changes during the capillaroscopic analysis in systemic sclerosis patients. Ann Rheum Dis 2008;67:885-887.[13] Sebastiani M, Manfredi A, Colaci M, DÁmico R, Malagoli V, Giuggioli D, Ferri C: Cappillaroscopic Skin Ulcer Risk Index: A New Prognostic Tool for Digital Skin Ulcer Development in systemic Sclerosis patients. Arthritis & Rheumathism2009: 61; 688-694.
[14] Nithyanova SI, Brough GM, Black CM, Denton CP: Clinical burden of digital vasculopaphy in limited and difuse cutaneos systemic sclerosis. Ann Rheum Dis 2008: 67; 120-123.
[15] Thompson AE, Pope JE.Calcium channel blockers for primary Raynaud’s phenomenon: a meta-analysis.Rheumatology (Oxford). 2005 Feb;44(2):145-50.
[16] Thompson e pope Calcium-channel blockers for Raynaud’s phenomenon in systemic sclerosis. Arthritis rheum2001; 44: 1841-7.
[17] M Dziadzio. Losartan therapy for Raynaud´s phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 1999.
[18] O Kowal-Bielecka, R Landewé, J Avouac, S Chwiesko, I Miniati, L Czirjak, P Clements, C Denton, D Farge, K Fligelstone, I Földvari, D E Furst, U Müller-Ladner, J Seibold, R M Silver, K Takehara, B Garay Toth, A Tyndall, G Valentini, F van den Hoogen, F Wigley, F Zulian, Marco Matucci-Cerinic, and the EUSTAR co-authorsEULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR) Ann Rheum Dis, May 2009; 68: 620-628.
[19] V Steen Digital ulcers: overt vascular disease in systemic sclerosis Rheumatology 2009 48(Supplement 3).
]]>